Charles River Laboratories International, Inc. (CRL)

Price$181.34

Value ScoreD

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-6.13%

Price vs S&P 500 (4W)2.10%

VGM Score44.71

Market Capitalization$8.73B

All Metrics

P/CF (Annual)11.84x

Book Value / Share (Quarterly)$61.05

P/TBV (Annual)3.54x

Revenue Growth (3Y)0.33%

Cash Flow / Share (Quarterly)$8.12

Price vs S&P 500 (YTD)-17.25%

Gross Margin (TTM)34.46%

Net Profit Margin (TTM)-4.59%

EPS (TTM)$-3.76

10-Day Avg Trading Volume0.88M

EPS Excl Extra (TTM)$-3.76

Revenue Growth (5Y)6.55%

EPS (Annual)$-2.91

ROI (Annual)-2.72%

Gross Margin (Annual)34.98%

Net Profit Margin (5Y Avg)6.28%

Cash / Share (Quarterly)$3.98

Revenue Growth QoQ (YoY)1.18%

ROA (Last FY)-2.02%

Revenue Growth TTM (YoY)0.11%

EBITD / Share (TTM)$4.05

ROE (5Y Avg)8.14%

Operating Margin (TTM)1.75%

Cash Flow / Share (Annual)$10.53

P/B Ratio2.97x

P/B Ratio (Quarterly)2.68x

Net Income / Employee (Annual)$-7,900

EV / Revenue (TTM)2.78x

Net Interest Coverage (TTM)0.22x

ROA (TTM)-2.47%

EV / EBITDA (TTM)56.20x

EPS Incl Extra (Annual)$-2.91

Current Ratio (Annual)1.29x

Quick Ratio (Quarterly)0.82x

3-Month Avg Trading Volume0.98M

52-Week Price Return28.43%

EV / Free Cash Flow (Annual)21.63x

Revenue / Employee (TTM)$220,100

Tangible BV / Share (Quarterly)$55.88

P/S Ratio (Annual)2.18x

Asset Turnover (Annual)0.56x

52-Week High$228.88

Operating Margin (5Y Avg)11.67%

EPS Excl Extra (Annual)$-2.91

CapEx CAGR (5Y)5.64%

Tangible BV CAGR (5Y)16.31%

26-Week Price Return1.80%

Quick Ratio (Annual)0.83x

13-Week Price Return0.01%

Total Debt / Equity (Annual)0.68x

Current Ratio (Quarterly)1.36x

Enterprise Value$11.21B

Revenue / Share Growth (5Y)6.99%

Asset Turnover (TTM)0.54x

Book Value / Share Growth (5Y)8.65%

Revenue / Employee (Annual)$219,400

Inventory Turnover (Annual)9.04x

Pretax Margin (Annual)-2.48%

Cash / Share (Annual)$4.34

3-Month Return Std Dev54.66%

Gross Margin (5Y Avg)36.25%

Net Income / Employee (TTM)$-10,100

EBITDA CAGR (5Y)-17.81%

EBITDA Interim CAGR (5Y)-2.37%

ROE (Last FY)-4.56%

Net Interest Coverage (Annual)-0.20x

EPS Basic Excl Extra (Annual)$-2.91

P/FCF (TTM)16.85x

Receivables Turnover (TTM)5.53x

EV / Free Cash Flow (TTM)28.66x

Total Debt / Equity (Quarterly)0.91x

EPS Incl Extra (TTM)$-3.76

Receivables Turnover (Annual)5.62x

ROI (TTM)-3.33%

P/S Ratio (TTM)2.17x

Pretax Margin (5Y Avg)8.63%

Revenue / Share (Annual)$81.01

Tangible BV / Share (Annual)$57.39

Forward P/E16.35x

Free OCF CAGR (5Y)6.41%

Price vs S&P 500 (52W)4.06%

Year-to-Date Return-9.09%

5-Day Price Return-0.40%

EPS Normalized (Annual)$-2.91

ROA (5Y Avg)3.18%

Net Profit Margin (Annual)-3.59%

Month-to-Date Return0.35%

Cash Flow / Share (TTM)$15.38

EBITD / Share (Annual)$4.12

Operating Margin (Annual)0.63%

LT Debt / Equity (Annual)0.67x

P/CF (TTM)14.39x

ROI (5Y Avg)4.22%

LT Debt / Equity (Quarterly)0.90x

EPS Basic Excl Extra (TTM)$-3.76

P/TBV (Quarterly)2.93x

P/B Ratio (Annual)3.16x

Inventory Turnover (TTM)8.12x

Pretax Margin (TTM)-4.11%

Book Value / Share (Annual)$64.30

Price vs S&P 500 (13W)-8.24%

Beta1.42x

P/FCF (Annual)16.85x

Revenue / Share (TTM)$82.27

ROE (TTM)-5.74%

52-Week Low$140.78

vGradeD

gGradeD

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 262.06est. 1.96

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.91

3.92

Industry Peers — R&D — Physical Sciences(15)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRLCharles River Laboratories International, Inc.	D	D	B	$181.34
IQVIQVIA Holdings Inc.	C	B	C	$183.45
INCYIncyte Genomics Inc	C	A	B	$102.38
MEDPMedpace Holdings, Inc. Common Stock	D	A	B	$454.25
ICLRIcon Plc	C	C	B	$149.45
ABSIAbsci Corporation Common Stock	F	F	A	$6.40
NRCNRC Health Common Stock	D	D	B	$19.14
OABIOmniAb, Inc. Common Stock	D	C	A	$2.48
MXCTMaxCyte, Inc. Common Stock	C	D	C	$1.14
ONMDOneMedNet Corp Class A Common Stock	D	C	B	$0.68
BIAFbioAffinity Technologies, Inc. Common Stock	C	F	B	$1.73

About

Charles River Laboratories is a leading provider of drug discovery and development services, operating since 1947. The company's three core segments—research models (supplying genetically characterized animal models for preclinical testing), discovery and safety assessment (early-stage drug development services), and manufacturing support (microbial solutions, in vitro testing, and biologics services)—position it as a critical partner throughout the pharmaceutical development lifecycle.